US2019388346A1PendingUtilityA1

Methods and compositions for treating osteoarthritis and promoting cartilage formation

58
Assignee: UNIV NEW YORKPriority: Sep 14, 2015Filed: Sep 4, 2019Published: Dec 26, 2019
Est. expirySep 14, 2035(~9.1 yrs left)· nominal 20-yr term from priority
Inventors:Bruce N. CronsteinCarmen Corciulo
A61K 31/53A61K 31/522A61K 31/519A61K 31/7076A61K 45/06A61K 47/24A61K 47/28A61K 47/44A61K 9/0019A61K 31/52A61P 19/02A61K 47/10A61K 9/127A61K 47/02A61K 31/517
58
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides methods and compositions for treating or inhibiting the development of osteoarthritis in a subject having osteoarthritis or at risk for developing osteoarthritis and for stimulating or increasing cartilage production or formation in a subject. The methods feature administering to the subject a therapeutically effective amount of a composition comprising one or more agent from among adenosine, an adenosine receptor agonist, and an agent that upregulates or increases the amount of or the biological activity of adenosine, or an analog or derivative thereof. The adenosine receptor may be an A 1 , A 2A , A 2B and A 3 adenosine receptor. The agent that upregulates or increases the amount of or the biological activity of adenosine may be dipyridamole or ticagrelor. The composition may be administered via intraarticular injection such as injection into the synovial fluid of a joint. The composition may be effective to reduce or inhibit degeneration or damage to cartilage or to stimulate or increase cartilage production or formation. The composition may be a liposomal composition or contain a liposome.

Claims

exact text as granted — not AI-modified
1 . A method for treating or inhibiting the development of osteoarthritis in a subject having osteoarthritis or at risk for developing osteoarthritis, comprising administering to the subject a therapeutically effective amount of a composition comprising one or more agent selected from the group consisting of adenosine, an adenosine receptor agonist, and an agent that upregulates or increases the amount of or the biological activity of adenosine, or an analog or derivative thereof. 
     
     
         2 . The method of  claim 1  wherein the adenosine receptor is selected from the group consisting of an A 1 , A 2A , A 2B  and A 3  adenosine receptor. 
     
     
         3 . The method of  claim 1  wherein and the adenosine receptor agonist is an adenosine receptor A 2A  agonist. 
     
     
         4 . The method of  claim 1  wherein and the adenosine receptor agonist is a selective adenosine receptor agonist. 
     
     
         5 . The method of  claim 1  wherein the agent that upregulates or increases the amount of or the biological activity of adenosine is dipyridamole or ticagrelor. 
     
     
         6 . The method of  claim 1  further comprising administering one or more other therapeutically effective compound or agent. 
     
     
         7 . The method of  claim 6  wherein the one or more other therapeutically effective compound or agent is selected from the group consisting of an anti-inflammatory compound, a bisphosphonate and a growth factor. 
     
     
         8 . The method of  claim 1  wherein the composition is administered via intraarticular injection. 
     
     
         9 . The method of  claim 1  wherein the composition is injected into synovial fluid of a joint. 
     
     
         10 . The method of  claim 1  wherein the composition is effective to reduce or inhibit degeneration or damage to cartilage. 
     
     
         11 . The method of  claim 1  wherein the composition is a liposomal composition or comprises a liposome. 
     
     
         12 . A method for stimulating or increasing cartilage production or formation in a subject comprising administering to the subject a therapeutically effective amount of a composition comprising one or more agent selected from the group consisting of adenosine, an adenosine receptor agonist, and an agent that upregulates or increases the amount of or the biological activity of adenosine, or an analog or derivative thereof. 
     
     
         13 . The method of  claim 12  wherein the adenosine receptor is selected from the group consisting of an A 1 , A 2A , A 2B  and A 3  adenosine receptor. 
     
     
         14 . The method of  claim 12  wherein and the adenosine receptor agonist is an adenosine receptor A 2A  agonist. 
     
     
         15 . The method of  claim 12  wherein and the adenosine receptor agonist is a selective adenosine receptor agonist. 
     
     
         16 . The method of  claim 12  wherein the agent that upregulates or increases the amount of or the biological activity of adenosine is dipyridamole or ticagrelor. 
     
     
         17 . The method of  claim 12  further comprising administering one or more other therapeutically effective compound or agent. 
     
     
         18 . The method of  claim 17  wherein the one or more other therapeutically effective compound or agent is selected from the group consisting of an anti-inflammatory compound, a bisphosphonate and a growth factor. 
     
     
         19 . The method of  claim 12  wherein the composition is administered via intraarticular injection. 
     
     
         20 . The method of  claim 12  wherein the composition is injected into synovial fluid of a joint. 
     
     
         21 . The method of  claim 12  wherein the composition is effective to reduce or inhibit degeneration or damage to cartilage. 
     
     
         22 . The method of  claim 12  wherein the composition is a liposomal composition or comprises a liposome. 
     
     
         23 . A composition comprising a therapeutically effective amount of one or more agent selected from the group consisting of adenosine, an adenosine receptor agonist, and an agent that upregulates or increases the amount of or the biological activity of adenosine, or an analog or derivative thereof. 
     
     
         24 . The composition of  claim 23  wherein the adenosine receptor is selected from the group consisting of an A 1 , A 2A , A 2B  and A 3  adenosine receptor. 
     
     
         25 . The composition of  claim 23  wherein the adenosine receptor agonist is an adenosine receptor A 2A  agonist. 
     
     
         26 . The composition of  claim 23  wherein the adenosine receptor agonist is a selective adenosine receptor agonist. 
     
     
         27 . The composition of  claim 23  wherein the agent that upregulates or increases the amount of or the biological activity of adenosine is dipyridamole or ticagrelor. 
     
     
         28 . The composition of  claim 23  further comprising one or more other therapeutically effective compound or agent. 
     
     
         29 . The composition of  claim 28  wherein the one or more other therapeutically effective compound or agent is selected from the group consisting of an anti-inflammatory compound, a bisphosphonate and a growth factor. 
     
     
         30 . The composition of  claim 23  wherein the composition is suitable for intraarticular injection. 
     
     
         31 . The composition of  claim 23  wherein the composition is suitable for injection into synovial fluid of a joint. 
     
     
         32 . The composition of  claim 23  wherein the composition is effective to reduce or inhibit degeneration or damage to cartilage or to stimulate or increase cartilage production or formation. 
     
     
         33 . The composition of  claim 23  wherein the composition is a liposomal composition or comprises a liposome.

Join the waitlist — get patent alerts

Track US2019388346A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.